Harvard Bioscience (NASDAQ: HBIO) and Illumina (NASDAQ:ILMN) are both computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares Harvard Bioscience and Illumina’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harvard Bioscience $104.52 million 1.07 -$4.30 million ($0.09) -35.56
Illumina $2.40 billion 13.25 $462.64 million $5.34 40.76

Illumina has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Harvard Bioscience and Illumina, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience 0 0 0 0 N/A
Illumina 1 8 11 0 2.50

Illumina has a consensus price target of $199.28, suggesting a potential downside of 8.44%. Given Illumina’s higher probable upside, analysts plainly believe Illumina is more favorable than Harvard Bioscience.

Profitability

This table compares Harvard Bioscience and Illumina’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harvard Bioscience -3.16% 1.11% 0.76%
Illumina 30.34% 19.42% 10.74%

Institutional & Insider Ownership

61.7% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 91.8% of Illumina shares are owned by institutional investors. 9.8% of Harvard Bioscience shares are owned by insiders. Comparatively, 0.9% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Harvard Bioscience has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Illumina has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Summary

Illumina beats Harvard Bioscience on 10 of the 13 factors compared between the two stocks.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.

Illumina Company Profile

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company’s portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.